enGene Holdings Inc. (NASDAQ:ENGN) Short Interest Down 31.9% in February

enGene Holdings Inc. (NASDAQ:ENGN - Get Free Report) was the target of a large drop in short interest in the month of February. As of February 28th, there was short interest totalling 60,300 shares, a drop of 31.9% from the February 13th total of 88,500 shares. Based on an average daily volume of 131,100 shares, the days-to-cover ratio is currently 0.5 days. Currently, 0.3% of the company's shares are sold short.

enGene Stock Up 4.9 %

Shares of NASDAQ ENGN traded up $0.25 during mid-day trading on Wednesday, reaching $5.40. The company had a trading volume of 21,681 shares, compared to its average volume of 131,048. The stock has a market capitalization of $275.28 million, a PE ratio of -9.31 and a beta of -0.61. enGene has a twelve month low of $4.42 and a twelve month high of $18.40. The company has a debt-to-equity ratio of 0.08, a quick ratio of 16.87 and a current ratio of 16.87. The stock's 50 day moving average is $6.41 and its 200-day moving average is $7.10.

enGene (NASDAQ:ENGN - Get Free Report) last posted its quarterly earnings results on Thursday, December 19th. The company reported ($0.34) earnings per share for the quarter, topping analysts' consensus estimates of ($0.40) by $0.06. As a group, equities analysts anticipate that enGene will post -1.56 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. JMP Securities restated a "market outperform" rating and set a $18.00 price objective on shares of enGene in a report on Monday, December 23rd. UBS Group lowered shares of enGene from a "buy" rating to a "neutral" rating and cut their price target for the company from $34.00 to $7.00 in a report on Friday, February 14th. Raymond James initiated coverage on shares of enGene in a research note on Wednesday, November 27th. They issued an "outperform" rating and a $23.00 price objective for the company. HC Wainwright reiterated a "buy" rating and set a $25.00 price objective on shares of enGene in a research report on Tuesday, March 11th. Finally, Morgan Stanley reduced their target price on enGene from $37.00 to $34.00 and set an "overweight" rating for the company in a report on Tuesday, March 11th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, enGene currently has a consensus rating of "Buy" and an average target price of $25.22.

Remove Ads

Hedge Funds Weigh In On enGene

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ENGN. Wolverine Asset Management LLC acquired a new position in shares of enGene during the 3rd quarter worth $37,000. Point72 Asset Management L.P. lifted its position in shares of enGene by 1,410.3% in the third quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company's stock worth $4,376,000 after buying an additional 619,100 shares during the last quarter. Franklin Resources Inc. lifted its position in shares of enGene by 48.7% in the third quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company's stock worth $7,854,000 after buying an additional 389,918 shares during the last quarter. Vontobel Holding Ltd. bought a new stake in shares of enGene during the 4th quarter worth about $69,000. Finally, Blue Owl Capital Holdings LP increased its holdings in shares of enGene by 3.3% during the 4th quarter. Blue Owl Capital Holdings LP now owns 3,159,975 shares of the company's stock valued at $21,014,000 after acquiring an additional 101,006 shares during the last quarter. Institutional investors own 64.16% of the company's stock.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.